The Anti-infective Vaccines Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Increased Occurrence of New and Re-emerging Infectious Illnesses Driving Market Growth
The rapid spread of novel infectious illnesses, which can lead to global outbreaks, is a big concern. This is happening as people get closer to wild creatures, travel longer distances, and live in more congested regions than ever before. There is also concern that diseases may be deliberately transferred to people, animals, or plants as part of terrorist activities. COVID-19, SARS, MERS, Ebola, chikungunya, avian flu, swine flu, and Zika are among the 40 infectious diseases detected. Future pandemics and outbreaks, experts warn, could be much more catastrophic than COVID-19. Because these contagious diseases are becoming more widespread, there will be a higher need for vaccines in the coming years. This will result in increased financing for R&D, a robust pipeline of novel vaccines, and more alternatives for a wide spectrum of people. This will propel the market forward.
High Cost of Immunisation Vaccines Likely to Challenge Industry Growth
The development of a vaccine is an expensive process. Vaccines, unlike other pharmaceutical items, necessitate specialised equipment and monitoring devices, resulting in greater storage and distribution costs. Inadequate infrastructure for storage and distribution may jeopardise the effectiveness and quality of immunisation initiatives. The process from in vitro research to marketing takes 10-15 years and costs between $800 million and $1 billion. Furthermore, because vaccine development has a poor success rate, firms frequently struggle with managing operational expenses and attracting initial finance. As a result, the increased costs associated with vaccine development and storage are acting as a barrier to market expansion.
What Questions Should You Ask before Buying a Market Research Report?
• How is the anti-infective vaccines market evolving?
• What is driving and restraining the anti-infective vaccines market?
• How will each anti-infective vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each anti-infective vaccines submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading anti-infective vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the anti-infective vaccines projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of anti-infective vaccines projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the anti-infective vaccines market?
• Where is the anti-infective vaccines market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the anti-infective vaccines market today, and over the next 10 years:
• Our 3053page report provides 112 tables, 157 charts /graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the anti-infective vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising anti-infective vaccines prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Vaccine Type
• Seasonal Influenza
• Shingles
• Tdap containing /DTaP Primary Vaccine
• Pneumococcal Conjugate Vaccine (PCV)
• Human Papillomavirus (HPV)
• Rotavirus
• Varicella
• Meningococcal
• Other Vaccines
Application Type
• Viral
• Bacterial
End-users
• Adult Vaccines
• Pediatric Vaccines
• Wide Ranging (Comprehensive) Vaccines
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Anti-infective Vaccines Market, 2023 to 2033, with a focus on this segment of these companies’ operations.
Leading companies profiled in the report
• AstraZeneca
• Bavarian Nordic
• BioDiem
• CSL
• Emergent
• Evotec SE
• Merck KGaA
• Mitsubishi Tanabe Pharma Corporation
• Pfizer Inc.
• Sanofi
• Serum Institute of India Pvt. Ltd.
• Sinovac
• Valneva SE
Overall world revenue for anti-infective vaccines market, 2023 to 2033 in terms of value the market will surpass US$48,300 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Anti-infective Vaccines Market, 2023 to 2033 report help you?
In summary, our 300+ page report provides you with the following knowledge:
• Revenue forecasts to 2033 for Anti-infective Vaccines, 2023 to 2033 Market, with forecasts for vaccine types, application types, and end-users types, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 24 key national markets – See forecasts for the Anti-infective Vaccines Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Germany, UK, France, Spain, Italy, Russia, China, India, Japan, Australia, South Korea, Singapore, Brazil, Mexico, Argentina, Colombia, GCC, South Africa, and among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 11 of the major companies involved in the Anti-infective Vaccines Market, 2023 to 2033.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the anti-infective vaccines market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Anti-infective Vaccines Market Report 2023-2033: Forecasts by Vaccine Type (Seasonal Influenza Vaccine, Shingles, Tdap Containing /DTaP Primary Vaccine, Pneumococcal Conjugate vaccine (PCV), Human Papillomavirus (HPV), Rotavirus, Varicella, Meningococcal, Other), by Application Type (Viral, Bacterial), by End-users (Adult Vaccines, Paediatric Vaccines, Wide Ranging (Comprehensive) Vaccines)) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Anti-infective Vaccines Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Pandemic Preparedness Driving Anti-Infective Vaccine Growth: A Paradigm Shift in Global Health
3.2.1.2 Increasing Prevalence of New and Re-emerging Infectious Diseases
3.2.1.3 Rising Demand for Tailored Vaccination Strategies is Driving Market Expansion
3.2.2 Market Restraining Factors
3.2.2.1 Substantial Expense of Immunization Vaccines Presents Notable Hindrances
3.2.2.2 Lack of Access to Anti-infective Vaccines in Underdeveloped Regions
3.2.3 Market Opportunities
3.2.3.1 Synergistic Collaboration Between Governments, International Health Organizations, and Vaccine Manufacturers
3.2.3.2 Increasing Funding Catalysing Advances in Vaccines and Infectious Disease Research
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
4 Anti-infective Vaccines Market Analysis by Vaccine Type
4.1 Key Findings
4.2 Vaccine Type Segment: Market Attractiveness Index
4.3 Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
4.4 Seasonal Influenza
4.4.1 Market Size by Region, 2023-2033 (US$ Million)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 Shingles
4.5.1 Market Size by Region, 2023-2033 (US$ Million)
4.5.2 Market Share by Region, 2023 & 2033 (%)
4.6 TdaP Containing /DTaP primary
4.6.1 Market Size by Region, 2023-2033 (US$ Million)
4.6.2 Market Share by Region, 2023 & 2033 (%)
4.7 Pneumococcal Conjugate Vaccine (PCV)
4.7.1 Market Size by Region, 2023-2033 (US$ Million)
4.7.2 Market Share by Region, 2023 & 2033 (%)
4.8 Human Papillomavirus (HPV)
4.8.1 Market Size by Region, 2023-2033 (US$ Million)
4.8.2 Market Share by Region, 2023 & 2033 (%)
4.9 Rotavirus
4.9.1 Market Size by Region, 2023-2033 (US$ Million)
4.9.2 Market Share by Region, 2023 & 2033 (%)
4.10 Varicella
4.10.1 Market Size by Region, 2023-2033 (US$ Million)
4.10.2 Market Share by Region, 2023 & 2033 (%)
4.11 Meningococcal
4.11.1 Market Size by Region, 2023-2033 (US$ Million)
4.11.2 Market Share by Region, 2023 & 2033 (%)
4.12 Other Vaccines
4.12.1 Market Size by Region, 2023-2033 (US$ Million)
4.12.2 Market Share by Region, 2023 & 2033 (%)
5 Anti-infective Vaccines Market Analysis by Application Type
5.1 Key Findings
5.2 Application Type Segment: Market Attractiveness Index
5.3 Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
5.4 Viral
5.4.1 Market Size by Region, 2023-2033 (US$ Million)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Bacterial
5.5.1 Market Size by Region, 2023-2033 (US$ Million)
5.5.2 Market Share by Region, 2023 & 2033 (%)
6 Anti-infective Vaccines Market Analysis by End-users
6.1 Key Findings
6.2 End-users Segment: Market Attractiveness Index
6.3 Anti-infective Vaccines Market Size Estimation and Forecast by End-users
6.4 Adult Vaccines
6.4.1 Market Size by Region, 2023-2033 (US$ Million)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Paediatric Vaccines
6.5.1 Market Size by Region, 2023-2033 (US$ Million)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Wide Ranging (Comprehensive) Vaccines
6.6.1 Market Size by Region, 2023-2033 (US$ Million)
6.6.2 Market Share by Region, 2023 & 2033 (%)
7 Anti-infective Vaccines Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast
8 North America Anti-infective Vaccines Market Analysis
8.1 Key Findings
8.2 North America Anti-infective Vaccines Market Attractiveness Index
8.3 North America Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
8.4 North America Anti-infective Vaccines Market Size Estimation and Forecast by Country
8.5 North America Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
8.6 North America Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
8.7 North America Anti-infective Vaccines Market Size Estimation and Forecast by End-users
8.8 U.S. Anti-infective Vaccines Market Analysis
8.9 Canada Anti-infective Vaccines Market Analysis
9 Europe Anti-infective Vaccines Market Analysis
9.1 Key Findings
9.2 Europe Anti-infective Vaccines Market Attractiveness Index
9.3 Europe Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
9.4 Europe Anti-infective Vaccines Market Size Estimation and Forecast by Country
9.5 Europe Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
9.6 Europe Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
9.7 Europe Anti-infective Vaccines Market Size Estimation and Forecast by End-users
9.8 Germany Anti-infective Vaccines Market Analysis
9.9 France Anti-infective Vaccines Market Analysis
9.10 UK Anti-infective Vaccines Market Analysis
9.11 Italy Anti-infective Vaccines Market Analysis
9.12 Spain Anti-infective Vaccines Market Analysis
9.13 Russia Anti-infective Vaccines Market Analysis
9.14 Rest of Europe Anti-infective Vaccines Market Analysis
10 Asia Pacific Anti-infective Vaccines Market Analysis
10.1 Key Findings
10.2 Asia Pacific Anti-infective Vaccines Market Attractiveness Index
10.3 Asia Pacific Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
10.4 Asia Pacific Anti-infective Vaccines Market Size Estimation and Forecast by Country
10.5 Asia Pacific Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
10.6 Asia Pacific Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
10.7 Asia Pacific Anti-infective Vaccines Market Size Estimation and Forecast by End-users
10.8 Japan Anti-infective Vaccines Market Analysis
10.9 China Anti-infective Vaccines Market Analysis
10.10 India Anti-infective Vaccines Market Analysis
10.11 Australia Anti-infective Vaccines Market Analysis
10.12 South Korea Anti-infective Vaccines Market Analysis
10.13 Singapore Anti-infective Vaccines Market Analysis
10.14 Rest of Asia Pacific Anti-infective Vaccines Market Analysis
11 Latin America Anti-infective Vaccines Market Analysis
11.1 Key Findings
11.2 Latin America Anti-infective Vaccines Market Attractiveness Index
11.3 Latin America Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
11.4 Latin America Anti-infective Vaccines Market Size Estimation and Forecast by Country
11.5 Latin America Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
11.6 Latin America Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
11.7 Latin America Anti-infective Vaccines Market Size Estimation and Forecast by End-users
11.8 Brazil Anti-infective Vaccines Market Analysis
11.9 Mexico Anti-infective Vaccines Market Analysis
11.10 Argentina Anti-infective Vaccines Market Analysis
11.11 Colombia Anti-infective Vaccines Market Analysis
11.12 Rest of Latin America Anti-infective Vaccines Market Analysis
12 MEA Anti-infective Vaccines Market Analysis
12.1 Key Findings
12.2 MEA Anti-infective Vaccines Market Attractiveness Index
12.3 MEA Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
12.4 MEA Anti-infective Vaccines Market Size Estimation and Forecast by Country
12.5 MEA Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
12.6 MEA Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
12.7 MEA Anti-infective Vaccines Market Size Estimation and Forecast by End-users
12.8 GCC Anti-infective Vaccines Market Analysis
12.9 South Africa Anti-infective Vaccines Market Analysis
12.10 Rest of MEA Anti-infective Vaccines Market Analysis
13 Company Profiles
13.1 Competitive Landscape, 2022
13.2 Strategic Outlook
13.1 Pfizer Inc.
13.1.1 Company Snapshot
13.1.2 Company Overview
13.1.3 Financial Analysis
13.1.3.1 Net Revenue, 2017-2022
13.1.3.2 R&D, 2017-2022
13.1.3.3 Regional Market Shares, 2022
13.1.4 Product Benchmarking
13.1.5 Strategic Outlook
13.2 AstraZeneca
13.2.1 Company Snapshot
13.2.2 Company Overview
13.2.3 Financial Analysis
13.2.3.1 Net Revenue, 2017-2022
13.2.3.2 R&D, 2017-2022
13.2.3.3 Regional Market Shares, 2022
13.2.4 Product Benchmarking
13.2.5 Strategic Outlook
13.3 Bavarian Nordic
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.3.1 Net Revenue, 2017-2022
13.3.3.2 R&D, 2017-2022
13.3.3.3 Regional Market Shares, 2022
13.3.4 Product Benchmarking
13.3.5 Strategic Outlook
13.4 Serum Institute of India Pvt. Ltd.
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Product Benchmarking
13.4.4 Strategic Outlook
13.5 BioDiem
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Product Benchmarking
13.6 Evotec SE
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Analysis
13.6.3.1 Net Revenue, 2017-2022
13.6.3.2 R&D, 2017-2022
13.6.3.3 Regional Market Shares, 2022
13.6.4 Product Benchmarking
13.6.5 Strategic Outlook
13.7 Sinovac
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.3.1 Net Revenue, 2017-2022
13.7.3.2 R&D, 2017-2022
13.7.4 Product Benchmarking
13.7.5 Strategic Outlook
13.8 Sanofi
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Product Benchmarking
13.8.4 Strategic Outlook
13.9 Merck KGaA
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis
13.9.3.1 Net Revenue, 2017-2022
13.9.3.2 R&D, 2017-2022
13.9.3.3 Regional Market Shares, 2022
13.9.4 Product Benchmarking
13.9.5 Strategic Outlook
13.10 CSL
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Financial Analysis
13.10.3.1 Net Revenue, 2017-2022
13.10.3.2 R&D, 2017-2022
13.10.3.3 Regional Market Shares, 2022
13.10.4 Product Benchmarking
13.10.5 Strategic Outlook
13.11 Emergent
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis
13.11.3.1 Net Revenue, 2017-2022
13.11.3.2 R&D, 2017-2022
13.11.4 Product Benchmarking
13.11.5 Strategic Outlook
13.12 Mitsubishi Tanabe Pharma Corporation
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Product Benchmarking
13.12.4 Strategic Outlook
13.13 GSK plc
13.13.1 Company Snapshot
13.13.2 Company Overview
13.13.3 Financial Analysis
13.13.3.1 Net Revenue, 2017-2022
13.13.3.2 R&D, 2017-2022
13.13.3.3 Regional Market Shares, 2022
13.13.4 Product Benchmarking
13.13.5 Strategic Outlook
13.14 Valneva SE
13.14.1 Company Snapshot
13.14.2 Company Overview
13.14.3 Financial Analysis
13.14.3.1 Net Revenue, 2017-2022
13.14.3.2 R&D, 2017-2022
13.14.3.3 Regional Market Shares, 2022
13.14.4 Product Benchmarking
13.14.5 Strategic Outlook
13.15 Novavax
13.15.1 Company Snapshot
13.15.2 Company Overview
13.15.3 Financial Analysis
13.15.3.1 Net Revenue, 2017-2022
13.15.3.2 R&D, 2017-2022
13.15.3.3 Regional Market Shares, 2022
13.15.4 Product Benchmarking
13.15.5 Strategic Outlook
14 Conclusion and Recommendations
14.1 Concluding Remarks from Visiongain
14.2 Recommendations for Market Players
List of Tables
Table 1 Anti-infective Vaccines Market Snapshot, 2023 & 2033 (US$ Million, CAGR %)
Table 2 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
Table 3 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
Table 4 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
Table 5 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
Table 6 Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 7 Seasonal Influenza Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 8 Shingles Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 9 TdaP Containing/ DTaP Primary Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 10 Pneumococcal Conjugate Vaccine (PCV) Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 11 Human Papillomavirus (HPV) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 12 Rotavirus Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 13 Varicella Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 14 Meningococcal Vaccine Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 15 Other Vaccine Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 16 Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 17 Viral Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 18 Bacterial Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 19 Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 20 Adult Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 21 Paediatric Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 22 Wide-ranging (comprehensive) vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 23 Anti-infective Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 24 North America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 25 North America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 26 North America Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 27 North America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 28 U.S. Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 29 Canada Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 30 Europe Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR %)
Table 31 Europe Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 32 Europe Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 33 Europe Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 34 Germany Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 35 France Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 36 UK Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 37 Italy Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 38 Spain Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 39 Russia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 40 Rest of Europe Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 41 Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 42 Asia Pacific Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 43 Asia Pacific Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 44 Asia Pacific Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 45 Japan Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 46 China Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 47 India Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 48 Australia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 49 South Korea Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 50 Singapore Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 51 Rest of Asia Pacific Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 52 Latin America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 53 Latin America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 54 Latin America Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 55 Latin America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 56 Brazil Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 57 Mexico Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 58 Argentina Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 59 Colombia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 60 Rest of Latin America Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 61 MEA Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 62 MEA Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 63 MEA Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 64 MEA Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 65 GCC Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 66 South Africa Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 67 Rest of MEA Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 68 Strategic Outlook
Table 69 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 Pfizer Inc.: Product Benchmarking
Table 71 Pfizer: Strategic Outlook
Table 72 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 AstraZeneca: Product Benchmarking
Table 74 AstraZeneca: Strategic Outlook
Table 75 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 Bavarian Nordic: Product Benchmarking
Table 77 Bavarian Nordic: Strategic Outlook
Table 78 Serum Institute of India Pvt. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Serum Institute of India Pvt. Ltd.: Product Benchmarking
Table 80 Serum Institute of India Pvt. Ltd.: Strategic Outlook
Table 81 BioDiem: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 BioDiem: Product Benchmarking
Table 83 Evotec SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Evotec SE: Product Benchmarking
Table 85 Evotec SE: Strategic Outlook
Table 86 Sinovac: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Sinovac: Product Benchmarking
Table 88 Sinovac: Strategic Outlook
Table 89 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Sanofi: Product Benchmarking
Table 91 Sanofi: Strategic Outlook
Table 92 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Merck KGaA: Product Benchmarking
Table 94 Merck: Strategic Outlook
Table 95 CSL: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 CSL: Product Benchmarking
Table 97 CSL: Strategic Outlook
Table 98 Emergent: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Emergent: Product Benchmarking
Table 100 Emergent: Strategic Outlook
Table 101 Mitsubishi Tanabe Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Mitsubishi Tanabe Pharma Corporation: Product Benchmarking
Table 103 Mitsubishi Tanabe Pharma Corporation: Strategic Outlook
Table 104 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 GSK plc: Product Benchmarking
Table 106 GSK: Strategic Outlook
Table 107 Valneva SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Valneva SE: Product Benchmarking
Table 109 Valneva SE: Strategic Outlook
Table 110 Novavax: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 Novavax: Product Benchmarking
Table 112 Novavax: Strategic Outlook
List of Figures
Figure 1 Anti-infective Vaccines Market Segmentation
Figure 2 Anti-infective Vaccines Market by Vaccine Type: Market Attractiveness Index
Figure 3 Anti-infective Vaccines Market by Application Type: Market Attractiveness Index
Figure 4 Anti-infective Vaccines Market by End-users: Market Attractiveness Index
Figure 5 Anti-infective Vaccines Market Attractiveness Index by Region
Figure 6 Anti-infective Vaccines Market: Market Dynamics
Figure 7 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): “V” Shaped Recovery
Figure 8 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): “U” Shaped Recovery
Figure 9 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): “W” Shaped Recovery
Figure 10 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): “L” Shaped Recovery
Figure 11 Anti-infective Vaccines Market: Porter’s Five Forces Analysis
Figure 12 Anti-infective Vaccines Market: PEST Analysis
Figure 13 Anti-infective Vaccines Market by Vaccine Type: Market Attractiveness Index
Figure 14 Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 15 Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023, 2028, 2033 (%)
Figure 16 Seasonal Influenza Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 17 Seasonal Influenza Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 18 Shingles Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 19 Shingles Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 20 TdaP Containing/ DTaP Primary Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 21 TdaP Containing/ DTaP Primary Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 22 Pneumococcal Conjugate Vaccine (PCV) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 23 Pneumococcal Conjugate Vaccine (PCV) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 24 Human Papillomavirus (HPV) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 25 Human Papillomavirus (HPV) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 26 Rotavirus Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 27 Rotavirus Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 28 Varicella Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 29 Varicella Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 30 Meningococcal Vaccine Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 31 Meningococcal Vaccine Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 32 Other Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 33 Other Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 34 Anti-infective Vaccines Market by Application Type: Market Attractiveness Index
Figure 35 Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
Figure 36 Anti-infective Vaccines Market Share Forecast by Application Type, 2023, 2028, 2033 (%)
Figure 37 Viral Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 38 Viral Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 39 Bacterial Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 40 Bacterial Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 41 Anti-infective Vaccines Market by End-users: Market Attractiveness Index
Figure 42 Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 43 Anti-infective Vaccines Market Share Forecast by End-users, 2023, 2028, 2033 (%)
Figure 44 Adult Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 45 Adult Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 46 Paediatric Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 47 Paediatric Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 48 Wide-ranging (comprehensive) vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 49 Wide-ranging comprehensive vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 50 Anti-infective Vaccines Market Forecast by Region 2023 and 2033 (Revenue, CAGR%)
Figure 51 Anti-infective Vaccines Market Share Forecast by Region 2023, 2028, 2033 (%)
Figure 52 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %)
Figure 53 North America Anti-infective Vaccines Market Attractiveness Index
Figure 54 North America Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 55 North America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 56 North America Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 57 North America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 58 North America Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 59 North America Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
Figure 60 North America Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 61 North America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 62 North America Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 63 U.S. Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 64 Canada Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 65 Europe Anti-infective Vaccines Market Attractiveness Index
Figure 66 Europe Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 67 Europe Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 68 Europe Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 69 Europe Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 70 Europe Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 71 Europe Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
Figure 72 Europe Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 73 Europe Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 74 Europe Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 75 Germany Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 76 France Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 77 UK Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 78 Italy Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 79 Spain Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 80 Russia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 81 Rest of Europe Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 82 Asia Pacific Anti-infective Vaccines Market Attractiveness Index
Figure 83 Asia Pacific Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 84 Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 85 Asia Pacific Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 86 Asia Pacific Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 87 Asia Pacific Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 88 Asia Pacific Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
Figure 89 Asia Pacific Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 90 Asia Pacific Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 91 Asia Pacific Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 92 Japan Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 93 China Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 94 India Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 95 Australia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 96 South Korea Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 97 Singapore Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 98 Rest of Asia Pacific Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 99 Latin America Anti-infective Vaccines Market Attractiveness Index
Figure 100 Latin America Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 101 Latin America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 102 Latin America Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 103 Latin America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 104 Latin America Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 105 Latin America Anti-infective Vaccines Market Forecast by Usage Type, 2023-2033 (US$ Million, AGR %)
Figure 106 Latin America Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 107 Latin America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 108 Latin America Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 109 Brazil Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 110 Mexico Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 111 Argentina Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 112 Colombia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 113 Rest of Latin America Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 114 MEA Anti-infective Vaccines Market Attractiveness Index
Figure 115 MEA Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
Figure 116 MEA Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
Figure 117 MEA Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
Figure 118 MEA Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
Figure 119 MEA Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
Figure 120 MEA Anti-infective Vaccines Market Forecast by Usage Type, 2023-2033 (US$ Million, AGR %)
Figure 121 MEA Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
Figure 122 MEA Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
Figure 123 MEA Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 124 GCC Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 125 South Africa Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 126 Rest of MEA Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 127 Pfizer Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 128 Pfizer Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 129 Pfizer Inc.: Regional Market Shares, 2022
Figure 130 AstraZeneca: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 131 AstraZeneca: R&D, 2017-2022 (US$ Million, AGR%)
Figure 132 AstraZeneca: Regional Market Shares, 2022
Figure 133 Bavarian Nordic: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 134 Bavarian Nordic: R&D, 2017-2022 (US$ Million, AGR%)
Figure 135 AstraZeneca: Regional Market Shares, 2022
Figure 136 Evotec SE: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 137 Evotec SE: R&D, 2017-2022 (US$ Million, AGR%)
Figure 138 Evotec: Regional Market Shares, 2022
Figure 139 Sinovac: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 140 Sinovac: R&D, 2017-2022 (US$ Million, AGR%)
Figure 141 Merck KGaA: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 142 Merck KGaA: R&D, 2017-2022 (US$ Million, AGR%)
Figure 143 Merck KGaA: Regional Market Shares, 2022
Figure 144 CSL: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 145 CSL: R&D, 2017-2022 (US$ Million, AGR%)
Figure 146 CSL: Regional Market Shares, 2022
Figure 147 Emergent: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 148 Emergent: R&D, 2017-2022 (US$ Million, AGR%)
Figure 149 GSK plc: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 150 GSK plc: R&D, 2017-2022 (US$ Million, AGR%)
Figure 151 GSK plc: Regional Market Shares, 2022
Figure 152 Valneva SE: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 153 Valneva SE: R&D, 2017-2022 (US$ Million, AGR%)
Figure 154 Valneva SE: Regional Market Shares, 2022
Figure 155 Novavax: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 156 Novavax: R&D, 2017-2022 (US$ Million, AGR%)
Figure 157 Novavax: Regional Market Shares, 2022
List of Companies Profiled in the Report
AstraZeneca
Bavarian Nordic
BioDiem
CSL
Emergent
Evotec SE
Merck KGaA
Mitsubishi Tanabe Pharma Corporation
Pfizer Inc.
Sanofi
Serum Institute of India Pvt. Ltd.
Sinovac
Valneva SE
List of Other Companies Mentioned in the Report
Affinivax, Inc.
Alydia Health
Astex Pharmaceuticals
Bayer AG
Batavia Biosciences
BB-NCIPD (Bul Bio)
Bharat Biotech
Biocon Biologics Limited (BBL)
Bristol Myers Squibb
Chimerix, Inc.
Chinook Therapeutics, Inc.
Dr. Reddy’s Laboratories Ltd.
Dynavax Technologies Corporation
Exothera
Gland Pharma
GSK plc
Hetero Biopharma
IDT Biologika
Johnson & Johnson
Moderna
Novavax, Inc.
List of Associations Mentioned in the Report
Biomedical Advanced Research and Development Authority (BARDA)
Centers for Disease Control and Prevention (CDC)
Coalition for Epidemic Preparedness Innovations (CEPI)
Committee for Medicinal Products for Human Use (CHMP)
European Commission (EC)
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
GAVI
Haute Autorité de santé (HAS)
Indian Council of Medical Research (ICMR)
International AIDS Vaccine Initiative (IAVI)
Medicines and Healthcare Products Regulatory Agency (MHRA)
National Health Service (NHS)
National Institute of Virology (NIV)
Servizio Sanitario Nazionale (SSN)
Vaccine and Infectious Disease Organization (VIDO)
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
